Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Thursday, October 13, 2016

Oromucosal Spray Improves Tough-to-Treat Spasticity in Patients With MS

I bet your doctor will never use this on your spasticity. I bet s/he never even hears about it. Time for you to educate your doctor again. $1000 an hour charge to your doctor sounds about right.It is cannabinoid based thus will never make it past our idiotic federal legislators having marijuana as a Class I drug.  Bet you have to go to Europe to try it.
http://www.docguide.com/oromucosal-spray-improves-tough-treat-spasticity-patients-ms?

: Presented at ECTRIMS By Jill Stein
LONDON -- September 17, 2016 -- New data support the use of a cannabinoid-based oromucosal spray as an add-on option to treat multiple sclerosis (MS)-related resistant spasticity.
The results, which are drawn from a large sample of patients treated with the spray in everyday clinical practice in Europe, were presented here at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Patrick Vermersch, MD, Universitaire de Lille, Lille, France, and colleagues collected data from 433 patients starting treatment with the spray at specialist centres in Italy, Norway, and Denmark.
The spray contains the active substances delta-9-tetrahydrocannabinol and cannabidiol (THC:CBD) at a ratio of 1:1.
The study aimed to augment the positive clinical findings from randomised clinical trials (RCTs) evaluating the spray.
All patients had moderate-to-severe MS spasticity and had not responded adequately to other anti-spasticity medications.
Effectiveness was measured by rates of treatment continuation and changes from baseline in scores on the spasticity numerical (0-10) rating scale (NRS) and the modified Ashworth scale (0-4).
After a 1-month trial period, patients who had achieved ≥20% improvement in their spasticity NRS score could continue.
Overall, 349 participants continued treatment with the spray beyond the first month visit, and 281 patients continued treatment beyond the third month visit.
Spasticity scores on all scales improved significantly improved in study completers at 3 months: 0-10 NRS (mean 6.9 to 5.4) and Ashworth scale (mean 2.6 to 2.3).
The usual 3-level categorical scale for the severity of spasticity (mild/moderate/severe) showed a marked reduction in severe cases from 37.2% to 12.9%.
The percentage of patients with no restrictions in their daily activities resulting from their spasticity was significantly reduced from 30.2% to 22.8%.
Roughly 20% of patients improved ≥30% on their NRS score.
Dr. Vermersch said that the results compare favourably with results from prior RCTs and observational studies.
Funding for this study was provided by Almirall S.A.
[Presentation title: Tetrahydrocannabinol + Cannabidiol Oromucosal Spray for Multiple Sclerosis-Resistant Spasticity on Daily Practice, New Data. Abstract P757]

No comments:

Post a Comment